Genomic landscape of HIV-1 proviruses in ART-treated immunological non-responders - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Genetic Profiling of HIV-1 Proviruses in Immunological Non-Responders Under Antiretroviral Therapy

  • By

  • Shengquan Tang

  • Yue Wang

  • Yanqiu Lu

  • Zhen Tong

  • Jiahui Guo

  • Yizhi Cui

  • Vijay Harypursat

  • Yemiao Chen

  • Jing Ouyang

  • Huan Li

  • Tong Wang

  • Quanhua Zhou

  • Yaokai Chen

  • August 12, 2026

Share

Clinical Scorecard: Genetic Profiling of HIV-1 Proviruses in Immunological Non-Responders Under Antiretroviral Therapy

At a Glance

CategoryDetail
ConditionHIV-1 Infection
Key MechanismsGenetic characteristics of HIV-1 reservoirs in immunological non-responders (INRs) versus immunological responders (IRs).
Target PopulationIndividuals living with HIV on antiretroviral therapy (ART).
Care SettingClinical research involving peripheral blood mononuclear cells (PBMCs) analysis.

Key Highlights

  • Higher levels of intact proviral genomes were observed in INRs compared to IRs.
  • Defective proviruses were the major component of the reservoir in both groups.
  • Proviral defects were predominantly found in the 3′ half of the genome.
  • INRs exhibit a unique proviral landscape linked to insufficient immune reconstitution.
  • The study emphasizes the need for further investigation into reservoir-targeted interventions.

Guideline-Based Recommendations

Diagnosis

  • Classify individuals as INRs or IRs based on CD4+ T-lymphocyte counts after ART.

Management

  • Consider additional investigations into the genetic integrity of HIV-1 reservoirs in INRs.

Monitoring & Follow-up

  • Monitor CD4+ T-lymphocyte counts and plasma viral loads in ART-treated individuals.

Risks

  • INRs have a higher susceptibility to opportunistic infections and non-AIDS-defining events.

Patient & Prescribing Data

ART-treated individuals with varying immune responses.

Understanding the genetic landscape of HIV-1 may inform future therapeutic strategies.

Clinical Best Practices

  • Ensure continuous ART for at least 24 months before evaluating immune response.
  • Utilize third-generation sequencing for detailed analysis of proviral genomes.

Related Resources & Content

    Original Source(s)

    Related Content